Arsenic Trioxide in Recurrent Urothelial Cancer: A Cancer and Leukemia Group B Phase II Trial (CALGB 99903) Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Arsenicals
  • Oxides
  • Urinary Bladder Neoplasms
  • Urologic Neoplasms
  • Urothelium

abstract

  • Arsenic trioxide at this dose and schedule does not have significant activity in previously treated urothelial cancer and has substantial toxicity in this patient population.

publication date

  • November 12, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.3816/CGC.2009.n.026

PubMed ID

  • 19815484

Additional Document Info

start page

  • E66

end page

  • 70

volume

  • 7

number

  • 3